Aspen offers excessive-pricing commitments
Aspen has said it will reduce its prices for six cancer drugs in Europe by an average of 73%, as part of a commitment package seeking to end the EU antitrust watchdog’s first excessive-pricing investigation in the pharmaceutical sector.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.